US Edition
News from oncnursingnews.com
We’ve assigned a media bias rating of unknown to oncnursingnews.com. You can read more about our methodology here.
If you want to know if oncnursingnews.com is credible or reliable, look no further. We rank oncnursingnews.com as Unknown factuality. Find out more about our methodology here.
Information about oncnursingnews.com
Where is oncnursingnews.com located?oncnursingnews.com's WebsiteMedia Bias Ratings
Do you disagree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top oncnursingnews.com News
FDA · United StatesOn Thursday, the U.S. Food and Drug Administration (FDA) approved Bristol Myers Squibb & Co.’s (NYSE:BMY) Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for adult patients with relapsed or refractory (R/R) marginal zone lymphoma (MZL). Breyanzi is administered as a one-time infusion. Breyanzi is now the only CAR T cell therapy approved by the FDA for five cancer types, the most of a…See the Story
What's Going On With Bristol-Myers Squibb Stock Friday? - Bristol-Myers Squibb (NYSE:BMY)
75% Center coverage: 4 sources
Chemotherapy-Based Conditioning Matches Outcomes of Total Body Irradiation for MRD-Negative B-ALL
100% Center coverage: 3 sources
Fixed-Duration or Continuous Therapy in CLL: Trial Says Take Your Pick
100% Center coverage: 1 sources
